Psoriasis vaccine - Immune Response BioPharma

Drug Profile

Psoriasis vaccine - Immune Response BioPharma

Alternative Names: IR-502

Latest Information Update: 08 Mar 2016

Price : $50

At a glance

  • Originator Immune Response Corporation
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Phase II Plaque psoriasis

Most Recent Events

  • 08 Mar 2016 Zorcell™ is still in phase IIb trials for Psoriasis in USA (IM, Injection)
  • 08 Mar 2016 Zorcell™ is available for licensing (http://www.immuneresponsebiopharma.com/Pages/Partnering.aspx)
  • 04 Feb 2014 Phase-IIb development of Zorcell™ is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top